483 related articles for article (PubMed ID: 19135109)
21. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy.
Hahnova-Cygalova L; Ceckova M; Staud F
Drug Metab Rev; 2011 Feb; 43(1):53-68. PubMed ID: 20854129
[TBL] [Abstract][Full Text] [Related]
22. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
Xu J; Peng H; Zhang JT
Curr Med Chem; 2007; 14(6):689-701. PubMed ID: 17346156
[TBL] [Abstract][Full Text] [Related]
23. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Lepper ER; Nooter K; Verweij J; Acharya MR; Figg WD; Sparreboom A
Pharmacogenomics; 2005 Mar; 6(2):115-38. PubMed ID: 15882131
[TBL] [Abstract][Full Text] [Related]
25. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Lemos C; Jansen G; Peters GJ
Br J Cancer; 2008 Mar; 98(5):857-62. PubMed ID: 18253130
[TBL] [Abstract][Full Text] [Related]
26. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.
Haimeur A; Conseil G; Deeley RG; Cole SP
Curr Drug Metab; 2004 Feb; 5(1):21-53. PubMed ID: 14965249
[TBL] [Abstract][Full Text] [Related]
27. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
Hasanabady MH; Kalalinia F
J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
[TBL] [Abstract][Full Text] [Related]
28. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
Seamon JA; Rugg CA; Emanuel S; Calcagno AM; Ambudkar SV; Middleton SA; Butler J; Borowski V; Greenberger LM
Mol Cancer Ther; 2006 Oct; 5(10):2459-67. PubMed ID: 17041089
[TBL] [Abstract][Full Text] [Related]
29. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
Hardwick LJ; Velamakanni S; van Veen HW
Br J Pharmacol; 2007 May; 151(2):163-74. PubMed ID: 17375082
[TBL] [Abstract][Full Text] [Related]
30. Impact of breast cancer resistance protein on cancer treatment outcomes.
Ross DD; Nakanishi T
Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
[TBL] [Abstract][Full Text] [Related]
31. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
[TBL] [Abstract][Full Text] [Related]
32. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
33. ABCG2: determining its relevance in clinical drug resistance.
Robey RW; Polgar O; Deeken J; To KW; Bates SE
Cancer Metastasis Rev; 2007 Mar; 26(1):39-57. PubMed ID: 17323127
[TBL] [Abstract][Full Text] [Related]
34. Human ABC transporter ABCG2 in xenobiotic protection and redox biology.
Wakabayashi K; Tamura A; Saito H; Onishi Y; Ishikawa T
Drug Metab Rev; 2006; 38(3):371-91. PubMed ID: 16877258
[TBL] [Abstract][Full Text] [Related]
35. BCRP/ABCG2 in the placenta: expression, function and regulation.
Mao Q
Pharm Res; 2008 Jun; 25(6):1244-55. PubMed ID: 18202831
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.
Wu ZX; Mai Q; Yang Y; Wang JQ; Ma H; Zeng L; Chen ZS; Pan Y
Biomed Pharmacother; 2021 Apr; 136():111223. PubMed ID: 33450491
[TBL] [Abstract][Full Text] [Related]
37. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
38. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).
Meyer zu Schwabedissen HE; Grube M; Dreisbach A; Jedlitschky G; Meissner K; Linnemann K; Fusch C; Ritter CA; Völker U; Kroemer HK
Drug Metab Dispos; 2006 Apr; 34(4):524-33. PubMed ID: 16415123
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).
Gandhi YA; Morris ME
AAPS J; 2009 Sep; 11(3):541-52. PubMed ID: 19629710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]